Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study

被引:0
|
作者
Han, DF
Zhou, X [1 ]
Hu, MB
Xie, W
Mao, ZF
Chen, DE
Liu, F
Zheng, F
机构
[1] Wuhan Univ, Zhongnan Hosp, Clin Lab Ctr, Wuhan 430071, Peoples R China
[2] Wuhan Univ, Zhongnan Hosp, Dept Oncol, Wuhan 430071, Peoples R China
[3] Wuhan Univ, Dept Publ Hlth, Wuhan 430071, Peoples R China
关键词
estrogen; metabolizing genes; polymorphism; breast neoplasms; risk factor;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Endogenous estrogen plays a very important role in the carcinogenesis and progression of breast cancer. The enzymes involved in the biosynthesis and metabolism of estrogen have been proposed to contribute to this effect. To examine this hypothesis, we conducted a case-control study to investigate the relationship between polymorphisms of genes responsible for estrogen biosynthesis (CYP17, cytochrome P450c17a and CYP19, aromatase cytochrome P450) and estrogen sulfation of inactivation (SULT1A1, sulfotransferaselA1) and the risk of breast cancer in Chinese women. Methods This study involved 213 breast cancer patients and 430 matched controls. PCR-based restriction fragment length polymorphism (RFLP) and short tandem repeat polymorphism (STRP) assays were used to detect the mononucleotide transition of CYP17 and SULT1A1 and tandem repeat polymorphism of CYP19. Logistic regression analyses were used to determine OR and 95% Cl of each and all three high-risk genotypes, of all three genotypes combined, and of estrogen exposure factors. The relationship between each high-risk genotype and clinical pathological characteristics were also assessed. Results The frequency of A(2) allele of CYP17 was 49.8% in cases and 49.1% in controls (P = 0.82). The frequency of His allele of SULT1A1 was significantly higher in cases (13.6%) than in controls (9.5%) (P < 0.05). There was also significant difference of the (TTTA)(10) allele of CYP19 which was 12.4% in cases and 8.2% in controls (P < 0.05). When the CYP17 A(2) allele, CYP19 (TTTA)(10) and SULT1A1 His allele were considered as the "putative high-risk" genotype, there was an increased risk of breast cancer with the number of high-risk genotypes in a dose-response effect (trend, P = 0.05). In multivariate analysis, the SULT1A1 genotype remained the most significant determinant for breast cancer, with OR = 2.37 (95% CI 1.23-4.74), followed by CYP19, with OR = 1.75 (95% CI 1.27-3.56). The (TTTA)(10) allele of CYP19 was associated with tumor size, and the His allele of SULT1A1 associated with status of lymph node metastasis. Conclusions This study supports the hypothesis that breast cancer can be initiated by estrogen exposure and that estrogen metabolizing genes are involved in this mechanism. This multigenic model is useful for identifying individuals who are at higher risks of breast cancer.
引用
收藏
页码:1507 / 1516
页数:10
相关论文
共 50 条
  • [2] Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study
    HAN Dingfen ZHOU Xin HU Mingbai XIE Wei MAO Zongfu CHEN Donge LIU Fang and ZHENG Fang Clinical Laboratory Center Department of Oncology Zhongnan Hospital of Wuhan University Wuhan China Public Health Department of Wuhan University Wuhan China
    ChineseMedicalJournal, 2005, (18)
  • [3] Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: A multigenic study on cancer susceptibility
    Cheng, TC
    Chen, ST
    Huang, CS
    Fu, YP
    Yu, JC
    Cheng, CW
    Wu, PE
    Shen, CY
    INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (03) : 345 - 353
  • [4] Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival
    Long, Ji-Rong
    Cai, Qiuyin
    Shu, Xiao-Ou
    Cai, Hui
    Gao, Yu-Tang
    Zheng, Wei
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (05): : 331 - 338
  • [5] Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease
    Lisa Gallicchio
    Sonja I Berndt
    Meghan A McSorley
    Craig J Newschaffer
    Lucy W Thuita
    Pedram Argani
    Sandra C Hoffman
    Kathy J Helzlsouer
    BMC Cancer, 6
  • [6] Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease
    Gallicchio, Lisa
    Berndt, Sonja I.
    McSorley, Meghan A.
    Newschaffer, Craig J.
    Thuita, Lucy W.
    Argani, Pedram
    Hoffman, Sandra C.
    Helzlsouer, Kathy J.
    BMC CANCER, 2006, 6 (1) : 1 - 11
  • [7] Polymorphisms of estrogen-metabolizing genes and risk of hepatocellular carcinoma in Taiwan females
    Yin, PH
    Lee, HC
    Chau, GY
    Liu, TY
    Liu, HC
    Lui, WY
    Chi, CW
    CANCER LETTERS, 2004, 212 (02) : 195 - 201
  • [8] Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT:: A multigenic study on cancer susceptibility
    Huang, CS
    Chern, HD
    Chang, KJ
    Cheng, CW
    Hsu, SM
    Shen, CY
    CANCER RESEARCH, 1999, 59 (19) : 4870 - 4875
  • [9] Association between estrogen-metabolizing genetic risk scores and breast cancer risk
    Andersen, Shaneda N. Warren
    Li, Guoliang
    Cai, Qiuyin
    Beeghly-Fadiel, Alicia
    Shrubsole, Martha J.
    Shu, Xiao-Ou
    Zheng, Wei
    CANCER RESEARCH, 2014, 74 (19)
  • [10] Lack of Association between the Functional Polymorphisms in the Estrogen-Metabolizing Genes and Risk for Hepatocellular Carcinoma
    Yuan, Xiaoyan
    Zhou, Gangqiao
    Zhai, Yun
    Xie, Weimin
    Cui, Ying
    Cao, Jia
    Zhi, Lianteng
    Zhang, Hongxing
    Yang, Hao
    Zhang, Xiaoai
    Qiu, Wei
    Peng, Yong
    Zhang, Xiumei
    Yu, Ling
    Xia, Xia
    He, Fuchu
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (12) : 3621 - 3627